Alzheimer's Disease Clinical Trials

Disease modifying drug trials. These test medicines meant to slow the disease itself, mostly by clearing amyloid or tau. They enroll people with early symptoms and confirmed plaques, run for 18 months or longer, and measure change on thinking and daily function scales. Brain MRI scans are frequent, because amyloid clearing drugs can cause swelling or small bleeds that need monitoring.

Prevention trials. The newest and possibly most important category. These enroll people with no symptoms who have amyloid in the brain, found by blood test or scan, and ask whether treating early can delay or prevent dementia. Some enroll people as young as 55 based on risk alone. If you have a family history and normal memory, this is the category to look at.

Symptom trials. Not everything targets the disease process. Studies test treatments for agitation, psychosis, sleep problems, and depression in people with Alzheimer's, symptoms that often weigh on families more than memory loss does.

Device and non drug trials. Light and sound stimulation at specific frequencies, focused ultrasound to open the brain's protective barrier, exercise programs, and cognitive training are all under study.

Diagnosis, biomarker, and observational studies. These follow people over years, collect blood and imaging, and develop better tests. They often welcome healthy older adults and people with a family history, and they are where the blood tests now reaching clinics came from. No treatment is promised in these studies.

Dementia is the general term for a decline in memory and thinking severe enough to affect daily life. Alzheimer's is the most common cause of it, responsible for 60 to 80 percent of cases. Other causes include vascular dementia, Lewy body dementia, and frontotemporal dementia.

It depends on the stage the study targets. Drug trials for early Alzheimer's usually require mild cognitive impairment or mild dementia, confirmed amyloid on a blood test, scan, or spinal fluid test, and a study partner, a family member or friend who can attend visits and report changes. Prevention trials enroll people with normal memory, often 55 to 80, who have amyloid or a strong risk profile. Symptom studies enroll people at moderate or later stages with agitation, psychosis, or sleep problems. Observational and biomarker studies frequently have the widest doors, including healthy volunteers. Some trials exclude people on blood thinners or with certain MRI findings, because of the bleeding risk with amyloid clearing drugs. Eligibility always varies by study.

• Preclinical. Amyloid is building in the brain, but memory is normal. This stage can last 15 to 20 years and is now detectable by blood test. Prevention trials enroll here.
• Mild cognitive impairment (MCI). Noticeable memory or thinking problems that do not yet disrupt daily life. The approved amyloid clearing drugs are for this stage and the next.
• Mild dementia. Symptoms begin to affect daily activities like managing money or medications. Still within the window for approved treatments.
• Moderate dementia. Help is needed with daily tasks; confusion, agitation, and sleep changes are common. Symptom trials focus here.
• Severe dementia. Full time care is needed. Research here centers on comfort, caregiver support, and quality of life.

Nearly every study names its stage in the title: "preclinical," "early symptomatic," "mild to moderate." Knowing where you or your loved one is, and whether amyloid has been confirmed, tells you at a glance which studies fit.

Enrolling in an Alzheimer's study through our platform takes about 5 minutes, and a family member can complete it on someone's behalf. Here is how it works:

Identify your trial. Use the search bar or filters. Titles usually name the stage ("early symptomatic," "preclinical," "mild to moderate"), so you can tell quickly which ones fit. If memory is normal but there is a family history, look for prevention and biomarker studies.

Select your preferred location. Enter your city or state in the filter on the left. Drug trials require repeated MRI scans and infusions at a study center, so distance matters; observational studies are often more flexible.

Explore study details. Click "Learn More" for goals, procedures, and eligibility, including whether amyloid confirmation is required, how many MRI visits are scheduled, and whether a study partner must attend.

Complete the health profile. Click "Get started" to begin the 5-step application. Have three things ready: the current diagnosis, if any (MCI, mild, or moderate dementia), any amyloid test results from a blood test, PET scan, or spinal tap, and the name of a study partner who can attend visits. Those answers decide eligibility for most Alzheimer's studies.

Submit the application. A clinical trial coordinator reviews it and contacts you about whether you or your loved one may qualify. Nothing is decided until you have gone through informed consent, which in Alzheimer's studies always includes the study partner, and participation is voluntary at every step.